Glucotrack ( GCTK, Financials) announced the pricing of a $3 million public offering of approximately 2.6 million shares of ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Here is why companies split their stocks and why it matters. Plus, upcoming stock splits from Southern Copper, cannabis ETFs, ...

Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...

In a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...